Immutep announces publication of ESMO 2023 abstracts
Filed with ASX · · 3 pages · English
Earlier from Immutep
- Commercial Scale Manufacturing of Efti for Clinical Trials
- Appendix 4E & 2023 Full Year Statutory Accounts
- Immutep receives positive scientific advice from EMA
- 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
- US patent granted for Efti with PD-1 pathway inhibitor
Later from Immutep
- Excellent Overall Survival in Non-Small Cell Lung Cancer
- Webcast slides for new Efti clinical data in 1st line NSCLC
- Immutep reports promising data from INSIGHT-003 trial
- New Biomarker Data from TACTI-002 trial in 1st line NSCLC
- Lead-in phase completed for ph2/3 trial in Breast Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep